Werewolf Therapeutics, Inc. — Director's Dealing 2021

May 4, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Werewolf Therapeutics, Inc. (HOWL)
CIK: 0001785530
Period of Report: 2020-12-08

Reporting Person: Seidel-Dugan Cynthia (Chief Scientific Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-12-08	Stock Option (right to buy)	$4.77	A	99163	Acquired	2030-12-07	Common Stock (99163)	Direct
2021-04-30	Stock Option (right to buy)	$16.00	A	57908	Acquired	2031-04-29	Common Stock (57908)	Direct

Footnotes

F1: The option was granted on December 8, 2020. The shares underlying the option vest over four years, with 25% of the shares vesting on the first anniversary of the grant date and 2.0833% of the shares vesting each month thereafter through December 8, 2024.

F2: The option was granted on April 30, 2021. The shares underlying the option vest over four years in equal monthly installments through April 30, 2025.